Equities

I'rom Group Co Ltd

2372:TYO

I'rom Group Co Ltd

Actions
Health CareHealth Care Providers
  • Price (JPY)2,598.00
  • Today's Change2.00 / 0.08%
  • Shares traded8.50k
  • 1 Year change+34.54%
  • Beta1.1772
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.

  • Revenue in JPY (TTM)17.89bn
  • Net income in JPY258.00m
  • Incorporated1997
  • Employees1.03k
  • Location
    I'rom Group Co Ltd5F/6FIidabashi Grand Bloom, 2-10-2, FujimiCHIYODA-KU 102-0071JapanJPN
  • Phone+81 332643148
  • Fax+81 332643147
  • Websitehttps://www.iromgroup.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
StemCell Institute Inc2.64bn423.14m16.65bn98.0039.355.8030.316.3041.3041.30257.79280.150.403925.621.6726,953,570.006.474.2315.3010.8563.4264.4016.0210.411.30--0.000.0018.6416.6357.0416.8446.68--
Saint-Care Holding Corp55.09bn1.74bn18.28bn4.74k10.481.116.680.331869.7469.742,208.76657.561.83383.106.3311,627,200.005.785.917.797.9912.3312.933.163.222.2420.740.234731.532.865.6317.0416.58-3.2012.30
CellSource Co Ltd4.45bn622.21m22.70bn151.0036.293.6830.795.1131.5831.58224.78311.550.74835.989.9429,442,380.0010.4719.2311.3722.5764.6470.7514.0020.2110.25--0.0012.895.5430.04-9.3036.7070.54--
Falco Holdings Co Ltd43.05bn1.83bn25.07bn1.12k13.370.93179.020.5825169.32169.323,990.492,428.931.1817.597.2538,538,940.005.025.796.417.9530.2731.284.254.662.29--0.020838.78-8.33-0.5259-26.3220.600.893711.70
Cyberdyne Inc4.39bn-1.18bn26.11bn227.00--0.9925--5.94-5.58-5.5820.81191.450.08732.227.7519,352,420.00-2.66-1.14-2.71-1.1652.6161.14-30.53-20.6814.00-10.610.0132--32.3820.57-395.30---22.40--
I'rom Group Co Ltd17.89bn258.00m32.03bn1.03k121.842.4921.771.7921.3121.311,477.811,044.220.5013.395.9917,387,760.000.7216.941.109.8739.6343.171.4411.341.1510.210.594831.02-3.3310.89-44.349.1816.6114.87
Sunwels Co Ltd23.37bn2.16bn33.39bn2.44k13.353.8310.871.4371.0171.01769.17247.450.88181,314.166.099,597,947.008.15--9.93--29.71--9.24--1.135.540.7342--55.72--159.16------
Charm Care Corp47.69bn4.45bn39.58bn2.03k8.902.157.320.83135.95135.951,458.21561.971.026.2315.0223,549,140.009.567.9217.9212.7418.1517.369.338.370.77997.630.424721.6626.2423.6333.3733.4744.0951.57
Elan Corp45.85bn2.46bn43.03bn378.0017.433.6114.280.938540.7340.73758.28196.492.4522.8510.01121,287,400.0013.1413.9022.0425.2723.0624.665.375.701.7253.110.010930.1514.2317.3920.9423.8213.7930.01
Solasto Corp136.54bn302.00m45.00bn33.88k147.032.0412.680.32963.233.231,476.44233.331.831,453.958.944,029,749.000.40375.400.59758.1816.4117.090.22122.941.3822.580.509254.163.099.91-28.85-8.4316.201.03
Data as of Nov 22 2024. Currency figures normalised to I'rom Group Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

6.18%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 30 Sep 2024255.60k2.07%
Asset Management One Co., Ltd.as of 15 Jul 2024158.50k1.29%
Nikko Asset Management Co., Ltd.as of 08 Nov 2024121.30k0.98%
Daiwa Asset Management Co. Ltd.as of 31 Oct 2024114.70k0.93%
Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 202452.20k0.42%
Dimensional Fund Advisors LPas of 07 Nov 202427.10k0.22%
BlackRock Japan Co. Ltd.as of 07 Nov 202414.80k0.12%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 19 Feb 202411.50k0.09%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 19 Feb 20243.50k0.03%
American Century Investment Management, Inc.as of 07 Nov 20242.90k0.02%
More ▼
Data from 30 Sep 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.